key: cord-0729409-fjpm6t9g
authors: Walsh, Kieran A.; Broderick, Natasha; Ahern, Susan; Fawsitt, Christopher G.; O’Brien, Katie M.; Carrigan, Marie; Harrington, Patricia; O’Neill, Michelle; Smith, Susan M.; Spillane, Susan; Teljeur, Conor; Ryan, Máirín
title: Effectiveness of rapid antigen testing for screening of asymptomatic individuals to limit the transmission of SARS‐CoV‐2: A rapid review
date: 2022-03-29
journal: Rev Med Virol
DOI: 10.1002/rmv.2350
sha: 3a8941f0e6a2334689b40c8f223f5234272500f5
doc_id: 729409
cord_uid: fjpm6t9g

Rapid antigen detection tests (RADTs) offer advantages over gold‐standard reverse transcription polymerase chain reaction (RT‐PCR) tests in that they are cheaper and provide faster results, thus enabling prompt isolation of positive SARS‐CoV‐2 cases and quarantine of close contacts. The aim of this study was to collate and synthesise empirical evidence on the effectiveness of rapid antigen testing for the screening (including serial testing) and surveillance of asymptomatic individuals to limit the transmission of SARS‐CoV‐2. A rapid review was undertaken in MEDLINE (EBSCO), EMBASE (OVID), Cochrane Library, Europe PMC and Google Scholar up until 19 July 2021, supplemented by a grey literature search. Of the identified 1222 records, 19 reports referring to 16 studies were included. Eight included studies examined the effectiveness of RADTs for population‐level screening, four for pre‐event screening and four for serial testing (schools, a prison, a university sports programme and in care homes). Overall, there is uncertainty regarding the effectiveness of rapid antigen testing for the screening of asymptomatic individuals to limit the transmission of SARS‐CoV‐2. This uncertainty is due to the inconsistent results, the relatively low number of studies identified, the predominantly observational and/or uncontrolled nature of the study designs used, and concerns regarding methodological quality. Given this uncertainty, more real‐world research evidence in relevant settings, which is of good quality and timely, as well as economic evaluation, is required to inform public policy on the widespread use of RADTs in asymptomatic individuals.

Since the onset of the Covid-19 pandemic, large-scale testing programmes have been rolled out globally, with hundreds of millions of individuals tested for SARS-CoV-2. 1 Many types of Covid-19 tests are now available for both clinical and public health use, some of which are laboratory based and others which can be performed in pharmacies, general practitioner clinics, schools, workplaces, airports and at home. 2 However, it is important that the right tests are undertaken in the right people at the right time for the right purpose, 3 as testing under the wrong circumstances may lead to test performance inaccuracies that cause harm to individuals and populations, and may not represent an efficient use of scarce healthcare resources. 4 Four different testing scenarios for SARS-CoV-2 have been described-diagnostic, close contact (including outbreaks), screening and surveillance-each of which serves different purposes and require different approaches. 2 Box 1 describes these four testing scenarios.

Reverse transcription polymerase chain reaction (RT-PCR) tests are considered the gold standard for diagnosing SARS-CoV-2 infection, 6 and they work by detecting fragments of the RNA genome of SARS-CoV-2. 1 However, given the very high sensitivity of RT-PCR tests, 6 individuals may continue to test positive for SARS-CoV-2 RNA for a prolonged period, 7 even when they are no longer infectious. 8 Rapid antigen detection tests (RADTs) work by detecting viral proteins (called antigens) on the surface of the virus. 9 RADTs offer advantages over RT-PCR tests in that they are cheaper (particularly if self-administered) 2 and provide faster results, thus enabling prompt isolation of positive cases and quarantine of their close contacts. 10 It is possible that the cases identified through RADTs are potentially the most infectious cases based on viral load. [11] [12] [13] However, it has been demonstrated in systematic reviews, 14, 15 including a Cochrane review, 6 that RADTs have significantly lower sensitivity overall than RT-PCR tests, particularly in asymptomatic populations (RADT sensitivity relative to RT-PCR: 72% [95% CI 63.7%-79.0%] in symptomatic individuals vs. 58.1% [95% CI 40.2%-74.1%] in asymptomatic individuals), 6 and have reduced positive predictive values (PPVs) in low prevalence settings. The Cochrane review on this topic estimated that for the devices assessed, at 0.5% infection prevalence, the use of RADTs in asymptomatic people would result in PPVs of 11%-28%, meaning that between 7 in 10 and 9 in 10 positive results would be false positives, and between 1 in 2 and 1 in 3 cases would be missed. 6 It has been argued that the repeated use of RADTs at a population level may overcome the issue of low sensitivity, and therefore may provide an effective means of reducing SARS-CoV-2

Diagnostic testing is intended to identify infection at an individual level and is performed when a person has signs or symptoms consistent with Covid-19. Aim is to identify infected individuals, so that medical care can be initiated where appropriate, and infection prevention and control (IPC) and public health measures implemented. Example: testing of a symptomatic person.

Close contact testing is intended to identify infection at an individual level and is performed when an individual is asymptomatic, but has had recent known or suspected exposure to SARS-CoV-2; this includes outbreak situations. Close contact testing may be considered a subset of diagnostic testing. Aim is to identify infected individuals, so that medical care can be initiated where appropriate, and IPC and public health measures implemented. Example: testing of an asymptomatic household contact.

Screening tests are performed in asymptomatic populations (showing no signs or symptoms consistent with Covid-19) who have no known, suspected, or reported exposure to SARS-CoV-2. Aim is to identify unknown cases so that measures can be taken to prevent further transmission. Example: screening of asymptomatic employees in a workplace.

Surveillance testing is primarily used to gain information at a population level, rather than an individual level, and generally involves testing of de-identified specimens. Aim is to monitor population-level burden of disease from a public health perspective. Example: wastewater surveillance.

Source: Adapted from the US Centers for Disease Control and Prevention (CDC). 5 2 of 14community transmission. 16 While findings from mathematical modelling studies support this hypothesis, [17] [18] [19] real-world evidence of effectiveness needs to be evaluated to determine if the expected benefits are realised in practice. Therefore, the aim of this rapid review was to collate and synthesise the empirical evidence on the effectiveness of rapid antigen testing for screening and surveillance of asymptomatic individuals at limiting the transmission of SARS-CoV-2.

We conducted a rapid review in accordance with a pre-defined protocol, 20 in keeping with Cochrane rapid review methodology guidance. 21 A systematic search of published peer-reviewed articles and non-peer-reviewed pre-prints was undertaken for all studies published up to 19 July 2021. No language restrictions were applied.

The following electronic databases were searched: MEDLINE (EBSCO), EMBASE (OVID), The Cochrane Library, Europe PMC and Google Scholar.

A grey literature search was conducted using the search string 'SARS-CoV-2', 'antigen testing' AND 'screening' on Google https://www.google.com/ on 19 July 2021. Government and public health agency websites as outlined in the protocol were searched on 16 July 2021. 20 Cited references and citations from relevant papers were screened using the Web of Science Core Collection database.

All potentially eligible papers were exported to Covidence (www.

covidence.org) for single screening of titles, abstracts and full texts for relevance based on the inclusion and exclusion criteria (Table 1) .

Population Asymptomatic (or pre-symptomatic) populations, in any setting Intervention SARS-CoV-2 rapid antigen testing for the purpose of screening (including serial testing) and surveillance.

No testing, or laboratory-based RT-PCR.

Primary outcomes ▪ transmission outcomes (e.g., infection rates, onward transmission [as measured by whole genome sequencing or contact tracing]). Secondary outcomes ▪ biological outcomes (e.g., concordance with RT-PCR or viral culture positivity) ▪ mortality ▪ healthcare utilisation outcomes (e.g., hospitalisation, intensive care unit (ICU) rates) ▪ behavioural outcomes (e.g., adherence to self-isolation, uptake of testing, knowledge, attitudes and beliefs) ▪ costs, resources and cost-effectiveness outcomes (e.g., cost per quality-adjusted life year [QALY] gained) ▪ time in quarantine/isolation (e.g., as a result of being identified as a positive case or close contact) ▪ time present for in-person education (e.g., for second-and third-level students).

Include:

▪ primary research studies including interventional studies, observational studies, ecological studies, and epidemiological investigations, of SARS-CoV-2 rapid antigen testing, where the aim of testing was screening or surveillance. unique studies ( Figure 1 ).

F I G U R E 1 PRISMA 2020 flow diagram of included studies. Record-The title or abstract (or both) of a report indexed in a database or website (such as a title or abstract for an article indexed in Medline). Records that refer to the same report (such as the same journal article) are 'duplicates'; however, records that refer to reports that are merely similar (such as a similar abstract submitted to two different conferences) are considered unique. Report-A document (paper or electronic) supplying information about a particular study. It could be a journal article, preprint, conference abstract, study register entry, clinical study report, dissertation, unpublished manuscript, government report, or any other document providing relevant information. Study-An investigation, such as a clinical trial, that includes a defined group of participants and one or more interventions and outcomes. A 'study' might have multiple reports. For example, reports could include the protocol, statistical analysis plan, baseline characteristics, results for the primary outcome, results for harms, results for secondary outcomes and results for additional mediator and moderator analyses 30, 33, 37 and Italy (South Tyrol). 28, 36, 40 The four pre-event screening studies, as well as the Italian population-based screening programme, used once-off rapid antigen testing 26, 28, 29, 34, 36, 39, 40 ; the prison testing programme con- 

All four population-based screening programmes, reported in eight studies 27, 28, [30] [31] [32] [33] [36] [37] [38] 40, 42 were initiated in the context of high SARS-CoV-2 incidence and relatively stringent background public health restrictions. All of the four countries undertaking populationbased screening programmes had re-imposed a lockdown within several weeks of commencing antigen testing in light of the rapidly deteriorating epidemiological situation and the emergence of variants of concern across Europe. 45 The number and intensity of public health measures implemented varied across studies, and no study relied solely on RADT for mitigation. Besides antigen testing, the most commonly implemented public health measures were health screening (e.g., temperature or symptoms) 26 

Three studies conducted by three different research teams were identified that evaluated the impact of multiple rounds of populationwide rapid antigen testing in October and November 2020 in Slovakia. 30, 33, 37 Coinciding with the introduction of a national lockdown, a pilot took place between 23 and 25 October in the four most WALSH ET AL. 37 Pavelka et al. conducted a before-after study and estimated changes in prevalence based on changes in RADT positivity between rounds of testing. 37 The positivity rate was 3.91% in the pilot, 1.01%

in round 1 and 0.62% in round 2. The authors estimated that the test positivity (assumed to be a proxy for prevalence) decreased by 58%

(95% CI, 57-58%) within 1 week in the 45 counties that were subject to at least two rounds of mass testing, after controlling for attendance rates, reproduction number and prevalence in previous rounds.

The authors further estimated that in the four counties that underwent three rounds of testing, observed infection prevalence decreased by 82% (95% CI, 81-83%) between the pilot and round 2.

Assuming an epidemic growth of 4.4% (95% CI, 1.1%-6.9%) per day preceding the mass testing campaign, the authors estimated that the decrease in prevalence compared with a scenario of unmitigated growth was 70% (95% CI, 67%-73%).

There have been a number of criticisms of this study, the most fundamental of which is the use of RADT positivity to measure changes in SARS-CoV-2 prevalence between rounds. 47 

Three studies by three different research teams evaluated the impact of a population-based screening programme in South Tyrol in North-Eastern Italy between 20 and 22 November 2020. 28 

Two studies by the same research group were conducted in Barcelona, Spain, to evaluate the effectiveness of pre-event RADT screening, plus respirator mask usage and adequate ventilation, without social distancing, at preventing SARS-CoV-2 transmission at live indoor music concerts. 34, 39 A randomised controlled trial (RCT) was conducted on 12

December 2020. 39 All study participants with a negative antigen test (tested by trained nurses within 9 h prior to the event) were rand- A follow-on study was conducted on 27 March 2021 with a larger sample size (n = 5000), using a before--after study design without a control group. 34 Same-day pre-event RADT screening was performed by trained nurses for all 5000 attendees. Of the 5000 people screened by RADT, 6 were found to be positive and 2 were close contacts of these positive cases, and so a total of 8 people were not allowed to enter the music event. The authors found that six attendees, none of whom were vaccinated, were diagnosed with SARS-CoV-2 infection within 2 weeks after the concert.

A comprehensive national event pilot programme called 'Fieldlab events' was conducted in the Netherlands. 48 All of these initial events WALSH ET AL. The authors concluded that the comprehensive mitigation measures that were in place, including serial antigen testing, prevented SARS-CoV-2 outbreaks in the prison. While no outbreaks were detected in this congregated setting during this study period, indicating that the layered mitigation approach was protective, the lack of comparators prevents ascertainment of the added benefit of the testing campaign to the existing measures.

Overall, 10 of the 16 studies were rated as 'fair' quality 26, 28, 29, [31] [32] [33] [34] [35] 39, 41, 42, 44 and 6 were rated as 'poor' quality. 27, 30, [36] [37] [38] 40, 43 No study was rated as 'good' quality (the highest quality rating; Supplementary material C).

Overall, there is uncertainty regarding the effectiveness of rapid antigen testing for screening of asymptomatic individuals at limiting the transmission of SARS-CoV-2. This uncertainty is due to the inconsistent results, the relatively low number of studies identified, the predominantly observational and/or uncontrolled study designs used, and concerns regarding the methodological quality of these studies. No studies were identified regarding the use of rapid antigen testing for surveillance of asymptomatic individuals.

While screening at a population-level using RADTs was reported by study authors in seven of the eight studies, 27, 28, [30] [31] [32] [33] [36] [37] [38] 42 to be effective at reducing SARS-CoV-2 transmission, it is important to note that the ecological design of these studies makes it very challenging to disentangle the contribution of mass testing from the ongoing background public health restrictions. The reported estimated effect on transmission varied from minimal change in one study 40 to an 82% reduction in prevalence after three rounds of testing in another study, 37 highlighting the significant uncertainty regarding the effectiveness of this intervention. Notably, the comparator groups in these studies were largely modelled and hypothetical, sometimes based on questionable assumptions. 27, 28, 30, 37, 38, 42 While estimates of effectiveness may vary, there was evidence from one included study that re-testing at regular intervals would likely be necessary for any potential sustained effect. 33 Moreover, it was evident that these population-based screening programmes were resource intensive, 27, 30, 36, 38 with uncertainty regarding their cost-effectiveness. 27 Additionally, despite the population-level screening programmes' stated objective of only testing asymptomatic individuals, it is possible that some people with symptoms may have attended as a means of rapidly availing of a test.

This may have influenced the pick-up rate of the programmes given that there is a higher PPV for RADTs in symptomatic individuals 6 ;

however, it may have also provided these individuals with a false sense of security given that the sensitivity of RADTs is lower than that of RT-PCR, 6 hence potentially facilitating riskier behaviours. 49 Better quality studies are needed to determine the effectiveness of RADT-based screening programmes, and whether such interventions represent value for money. Such a study may involve randomising by geographical area, the offer of repeated testing in asymptomatic people versus no offer of testing, and the conduct of an economic evaluation. 4 While there was some evidence that repeated mass testing using 39 Of note, this study did not detect any positive cases using RADTs pre-event.

However, knowledge of planned pre-event testing may have acted as a deterrent for prospective attendees who were aware that they had symptoms or that they had been recently exposed to SARS-CoV-2.

Awareness of the planned pre-event testing could also have altered prospective attendees' behaviours to engage better in mitigation measures in the days leading up to the event.

A recently published study found that the intensive Danish mass testing strategy (using both RT-PCR and RADTs) did not significantly reduce the prevalence of SARS-CoV-2 and had no impact on the number of hospitalisations. 52 The authors suggested that the mass testing may have increased risk behaviours of those tested, or that WALSH ET AL. where screening missed some infectious cases despite the implementation of mandatory directly observed daily antigen testing. 35 Though RADTs may be relatively inexpensive and easy to administer at an individual level, 16 real-world evidence from included studies highlights the significant resource, implementation and social issues associated with using RADTs at scale. 26, 27, 29, 30, 34, 36, 38, 39, 41, 42 For example, the largest of the included screening programmes that took place in Slovakia involving over 5 million RADTs, cost over €82 million, 30 and involved over 60,000 personnel. 37 Tulloch et al.

described barriers to the implementation of a bi-weekly RADT protocol in care homes in Liverpool, which included inadequate training, insufficient capacity and lack of suitable areas to conduct the testing, which culminated in poor adherence to the testing protocol, despite the high risk setting. 41 In the population-level screening pilots con- 

A strength of this rapid review is the focus on the clinical effectiveness of RADTs in real-world situations rather than diagnostic test accuracy. In this way, primacy is given to outcomes that are of greater relevance to the public and to policy-makers (such as infection and hospitalisation rates), rather than technical performance issues (such as sensitivity and specificity). 55 A number of limitations need to be considered when interpreting the findings of this rapid review. Only one included study was an RCT, 39 That is, knowing that individuals are due to be screened may increase awareness and adherence, or equally it could plausibly give rise to risk compensation. Therefore engaging in screening may change behaviour in a manner that alters the effect of the intervention relative to the counterfactual of no screening. This creates challenges for evaluating an intervention in the absence of a randomised control group.

Importantly, all included studies were published on or before 19

July 2021 and were, therefore, conducted before the emergence of the Delta or Omicron variants of concern. The Covid-19 epidemiological situation can change rapidly due to variants, and this may have implications for the diagnostic test accuracy of RADTs, both in terms of causing increased prevalence and hence higher PPVs, 56 All studies had noted methodological issues with none being assessed to be of 'good' quality, which lowers the overall certainty of the evidence. Additionally, studies evaluating the effectiveness of RADTs in asymptomatic populations may be subject to publication bias. This is where studies with favourable outcomes are more likely to be published in the academic literature, than those with negative findings. 59

Overall, there is uncertainty regarding the effectiveness of RADTs for screening in asymptomatic individuals, with no evidence found regarding their use for surveillance purposes at the time of writing. It is important to note that the studies included within this review were conducted before the emergence of the Delta and Omicron variants.

As such, it is possible that the findings may be specific to scenarios of transmission that pre-dated these variants. Given uncertainty surrounding the clinical-and cost-effectiveness of RADT-based screening programmes in asymptomatic individuals to limit the transmission of SARS-CoV-2, more real-world research evidence in relevant settings, which is of good quality and timely, as well as economic evaluation, is required to inform public policy on the widespread use of RADTs in asymptomatic individuals. In light of these uncertain results from empirical evidence, data on the effectiveness of RADT screening based solely on modelling should be interpreted with caution. Where RADTs are being considered for screening asymptomatic populations, these should be considered as an additional public health measure, rather than a replacement for known mitigation measures (such as face masks, vaccination and physical distancing).

Testing at scale during the COVID-19 pandemic

COVID-19 testing: one size does not fit all

Rapid Health Technology Assessment of Alternative Diagnostic Testing Approaches for the Detection of Severe Acute Respiratory Syndrome Coronavirus

Asymptomatic rapid testing for SARS-CoV-2

US Centers for Disease Control and Prevention. Overview of Testing for SARS-CoV-2 (COVID-19)

Rapid, point-of-care antigen and molecular-based tests for diagnosis of SARS-CoV-2 infection

SARS-CoV-2 detection, viral load and infectivity over the course of an infection

The duration of infectiousness of individuals infected with SARS-CoV-2

Rapid Health Technology Assessment (HTA) of Alternatives to Laboratory-Based Real-Time RT-PCR to Diagnose Current Infection with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). HIQA

Put to the test: use of rapid testing technologies for Covid-19

Presymptomatic SARS-CoV-2 infections and transmission in a skilled nursing facility

Epidemiologic characteristics associated with SARS-CoV-2 antigen-based test results, rRT-PCR cycle threshold values, subgenomic RNA, and viral culture results from university testing

Evaluation of Abbott BinaxNOW rapid antigen test for SARS-CoV-2 infection at two community-based testing sites-Pima County

Accuracy of novel antigen rapid diagnostics for SARS-CoV-2: a living systematic review and meta-analysis

Factors that influence the reported sensitivity of rapid antigen testing for SARS-CoV-2. Front Microbiol

Rethinking Covid-19 test sensitivity-a strategy for containment

Assessment of SARS-CoV-2 screening strategies to permit the safe reopening of college campuses in the United States

Test sensitivity is secondary to frequency and turnaround time for COVID-19 screening

Potential Impact of Different Serial Testing Scenarios Using Rapid Antigen Detection Tests (RADTs) to Detect SARS-CoV-2 in Meat Processing Plant Workers; 2021. Updated

Protocol: Evidence Summary for Use of Rapid Antigen Testing for Screening or Surveillance of Asymptomatic Individuals to Limit Transmission of SARS-CoV-2; 2021. Updated

Cochrane Rapid Reviews Methods Group offers evidence-informed guidance to conduct rapid reviews

Study Quality Assessment Tools

Coronavirus Pandemic (COVID-19). OurWorldInData.org; 2020. Cited

The PRISMA 2020 statement: an updated guideline for reporting systematic reviews

Events Research Programme: Phase 1 Findings

Costeffectiveness of whole area testing of asymptomatic SARS-CoV-2 infections in Merthyr Tydfil, 2020: a modelling and economic analysis. medRxiv

Does Covid-19 Mass Testing Work? The Importance of Accounting for the Epidemic Dynamics

Request for Advice Reopening Events -Type III, Outside Active

On pilot massive COVID-19 testing by antigen tests in Europe. Case study: Slovakia

Performance of the Innova SARS-CoV-2 antigen rapid lateral flow test in the Liverpool WALSH ET AL

asymptomatic testing pilot: population based cohort study

Evaluating social and spatial inequalities of large scale rapid lateral flow SARS-CoV-2 antigen testing in COVID-19 management: an observational study of Liverpool

The impact of repeated mass antigen testing for COVID-19 on the prevalence of the disease

Screening for SARS-CoV-2 antigen before a live indoor music concert: an observational study

Severe acute respiratory syndrome coronavirus 2 transmission in intercollegiate athletics not fully mitigated with daily antigen testing

Analysis of Mass Test Results in the Autonomous Province of Bolzano

CMMID COVID-19 Working Group. The impact of population-wide rapid antigen testing on SARS-CoV-2 prevalence in Slovakia

Evaluation of the Lateral Flow Device Testing Pilot for COVID-19 in Merthyr Tydfil and the Lower Cynon Valley

Same-day SARS-CoV-2 antigen test screening in an indoor mass-gathering live music event: a randomised controlled trial

Rapid antigen tests for large-scale diagnostic campaigns: a case study from North-Eastern Italy

Enhanced Lateral Flow Testing Strategies in Care Homes Are Associated with Poor Adherence and Were Insufficient to Prevent COVID-19 Outbreaks: Results from a Mixed Methods Implementation Study

COVID-19 testing to sustain in-person instruction and extracurricular activities in high schools

Efficacy of the measures adopted to prevent COVID-19 outbreaks in an Italian correctional facility for inmates affected by chronic diseases. Front Public Health

European Centre for Disease Prevention and Control. Risk Related to the Spread of New SARS-CoV-2 Variants of Concern in the EU/EEA -First Update

Characteristic spatial scales of SARS-CoV-2 pandemics: lessons from mass rapid antigen testing in Slovakia. medRxiv

Technical Comment on the Impact of Population-Wide Rapid Antigen Testing on SARS-CoV-2 Prevalence in Slovakia

Fieldlab Events; 2021

Durham University students' experiences of asymptomatic COVID-19 testing: a qualitative study

Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England

Effectiveness of public health measures to prevent the transmission of SARS-CoV-2 at mass gatherings: a rapid review

Assessment of the national test strategy on the development of the COVID-19 pandemic in Denmark

Association between SARS-CoV-2 transmissibility, viral load, and age in households. medRxiv

A rapid review of measures to support people in isolation or quarantine during the Covid-19 pandemic and the effectiveness of such measures

Evaluating tests for diagnosing COVID-19 in the absence of a reliable reference standard: pitfalls and potential solutions

Rapid Diagnostic Tests for Covid-19; 2020

Detection of the new SARS-CoV-2 variants of concern B.1.1.7 and B.1.351 in five SARS-CoV-2 rapid antigen tests (RATs)

Diagnostic efficacy of rapid antigen testing for SARS-CoV-2: the COVid-19 AntiGen (COVAG) Study. medRxiv

Publication bias: what are the challenges and can they be overcome?

Effectiveness of rapid antigen testing for screening of asymptomatic individuals to limit the transmission of SARS-CoV-2: a rapid review

The authors would like to acknowledge the support of the Health Technology Assessment Directorate at HIQA. This research was funded in part by the Health Research Board under grant no. HRB-